SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share.

圣迭戈，2026年10月15日（环球电讯社）——First Tracks Biotherapeutics, Inc.（纳斯达克股票代码：TRAX），一家处于临床阶段的生物技术公司，致力于推进调节与自身免疫性和炎症性疾病相关免疫通路的抗体疗法，今日宣布已与有限数量的机构投资者签订证券购买协议，以每股32.75美元的价格通过私募方式向其出售6,106,870股普通股。

First Tracks Biotherapeutics anticipates approximately $200 million in gross proceeds to the company before deducting placement agent fees and other expenses. Closing of the private placement is expected to occur on October 19, 2026, subject to the satisfaction of customary closing conditions..

First Tracks Biotherapeutics 预计，在扣除配售代理费及其他费用之前，公司将获得约2亿美元的总收益。此次私募配售的交割预计将于2026年10月19日完成，前提是满足惯常的交割条件。

The private placement included participation from new and existing investors including Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital, a life sciences-focused institutional investor and multiple leading mutual funds.

本次私募配售吸引了新老投资者的参与，包括Affinity Asset Advisors, LLC、First Light Asset Management、Sirenia Capital Management LP、TCGX、Trails Edge Capital Partners、Vestal Point Capital（一家专注于生命科学的机构投资者）以及多家领先的共同基金。

.

。

First Tracks Biotherapeutics intends to use the proceeds from the private placement for general corporate purposes, including for clinical development of ANB033, a CD122 antagonist.

First Tracks Biotherapeutics 计划将私募配售所得资金用于一般公司用途，包括用于 CD122 拮抗剂 ANB033 的临床开发。

Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities are acting as placement agents for the private placement.

Leerink Partners、Piper Sandler、瑞银投资银行和富国银行证券担任此次私募发行的配售代理。

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities will not and have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States absent registration or an applicable exemption from registration requirements.

上述证券的发售与销售系以不涉及公开发行的方式进行，且该等证券未曾并将不会根据经修订的《1933年证券法》进行注册；除非完成注册或适用注册要求的豁免，否则不得在美国境内再次发售或转售。

First Tracks Biotherapeutics has agreed to file a registration statement with the SEC registering the resale of the common stock sold in the private placement..

First Tracks Biotherapeutics 已同意向美国证券交易委员会（SEC）提交一份注册声明，以登记其在私募配售中出售的普通股的转售。

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售任何此处所述证券的要约，也不构成购买此类证券的要约邀请；在任何州或其他司法管辖区，若根据该州或司法管辖区的证券法律，在此类要约、要约邀请或销售尚未完成注册或资格认定之前进行上述行为属违法，则不得在该州或司法管辖区销售这些证券。

About First Tracks Biotherapeutics

关于 First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.

First Tracks Biotherapeutics 是一家处于临床阶段的生物技术公司，致力于推进调节与自身免疫性和炎症性疾病相关免疫通路的抗体疗法。其产品管线包括：ANB033，一种正在开发中用于治疗乳糜泻和嗜酸性粒细胞性食管炎的 CD122 拮抗剂；rosnilimab，一种正在开发中用于治疗类风湿关节炎的致病性 T 细胞清除剂；以及 ANB101，一种 BDCA2 调节剂。

To learn more, visit .

欲了解更多信息，请访问。

www.FirstTracksBio.com

www.FirstTracksBio.com

or follow us on

或在以下平台关注我们

LinkedIn

领英

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements relating to the expected timing of closing of the private placement, the intended use of proceeds and the filing of a registration statement.

本新闻稿包含1995年《私人证券诉讼改革法》“安全港”条款所定义的前瞻性陈述，包括但不限于：有关私募配售预计完成时间、募集资金的预期用途以及提交注册声明的陈述。

Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements.

包含“计划”、“继续”、“预期”或“持续”等词语的陈述，以及使用将来时态的陈述，均属于前瞻性陈述。这些前瞻性陈述涉及风险、不确定性以及假设；如果这些风险、不确定性或假设未能完全实现或被证明不正确，则可能导致实际结果与前述前瞻性陈述所明示或暗示的结果存在重大差异。

Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission.

前瞻性陈述受限于各种风险和不确定性，这些风险和不确定性可能导致公司的实际活动或结果与任何前瞻性陈述中表达的内容存在重大差异，包括与公司推进候选产品、获得监管批准并最终实现候选产品商业化能力相关的风险和不确定性，临床前和临床试验的时间安排及结果，公司为开发活动提供资金并实现开发目标的能力，公司保护知识产权的能力，以及公司在不时向美国证券交易委员会提交的文件中“风险因素”标题下描述的其他风险和不确定性。

These forward-looking statements speak only as of the date hereof, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof..

这些前瞻性陈述仅反映截至本文发布之日的情况，公司不承担修订或更新任何前瞻性陈述以反映本文发布之日后发生的事件或情况的义务。

Investor Contact:

投资者联系：

Nick Montemarano

尼克·蒙特马兰诺

Vice President, Investor Relations

投资者关系副总裁

858.732.0178

858.732.0178

investors@firsttracksbio.com

investors@firsttracksbio.com